MIT’s LUCID Ultrasound Implant Extends Glioblastoma Drug Reach

MIT researchers have developed LUCID, a flexible implantable device that uses ultrasound to extend the reach of drugs delivered directly into the brain, with primary application in glioblastoma. Published in Device on 27 October 2026, the Long-term Ultrasound-enhanced Convective Injection Device combines a drug-delivery cannula with 24 miniature ultrasound transducers and wireless control, opening a differentiated commercial path across the convection-enhanced delivery and intracranial drug delivery categories.

LUCID is described as about as thin as cardstock, with a 3D-printed drug-delivery cannula mounted onto an array of 24 miniature ultrasound transducers that generate ultrasound at the needle tip. A 100-microlitre reservoir drives infusion via passive osmotic pump, with Bluetooth-controlled ultrasound dosing and wireless battery recharging. In clinical use, the cannula and transducers would sit inside the skull while the battery and electronics would remain outside. The ultrasound component works through two mechanisms: convective flow carrying molecules farther through tissue, and mechanical oscillations temporarily increasing blood-brain barrier permeability. Preclinical tissue phantom and mouse MRI contrast agent studies both demonstrated extended drug distribution with ultrasound activation.

Senior author Canan Dagdeviren, Associate Professor at MIT Media Lab, led the work with lead authors Sarah Ornellas and Jason Hou. The device builds on Dagdeviren’s earlier cannula and ImPULS deep-brain-stimulation implant platform. Glioblastoma remains the primary target indication, with approximately 10,000 US cases annually and average survival of just 12-15 months post-diagnosis driving substantial unmet medical need. The device could potentially be implanted during tumour resection surgery for ongoing post-operative drug delivery. The platform sharpens competitive positioning across the glioblastoma therapeutic category dominated by Novocure (Optune Gio tumor treating fields), Novartis (Temodar/temozolomide), Roche (Avastin), and emerging intracranial drug delivery specialists Alcyone Therapeutics, Insightec (focused ultrasound BBB opening), CarThera (SonoCloud) and Bioxcel Therapeutics. The approach could also deliver immunotherapies, nucleic acids and gene therapies.

The commercial signal is an emerging ultrasound-enhanced intracranial drug delivery category where device-based BBB disruption and convection-enhanced delivery open substantial opportunity against glioblastoma’s limited therapeutic landscape. Clinical translation remains early-stage. Expect MIT spin-outs, Novocure, Novartis, Roche, Insightec, CarThera, Alcyone Therapeutics and intracranial drug delivery specialists to monitor ultrasound-enhanced delivery through 2027 and 2028.

For the latest updates and in-depth insights into the world of Medical Devices, including breakthrough treatments, industry trends, and regulatory news, contact  Albert Baines today!